

## MEDICAL GRAND ROUNDS 2011-2012

**SEPTEMBER 12**

### **WIKILEAKS INSIGHTS INTO GUIDELINES DEVELOPMENT - A FOCUS ON THE ECHOCARDIOGRAPHIC ASSESSMENT OF THE RIGHT HEART**

**Lawrence Rudski, MD, FACC FASE**

Associate Professor of Medicine  
McGill University  
Director, Non-Invasive Cardiology  
Associate Director, Division of Cardiology  
Jewish General Hospital

#### **Educational Objectives:**

1. Understand the process of guidelines development as applied to echocardiography
2. Understand basic principles of cardiac ultrasound
3. Understand the methods of evaluation of the right heart by echocardiography

**SEPTEMBER 19**

### **PERSONALIZED MEDICINE IN CANCER, GETTING THERE**

**Gerald Batist, MD**

Minda de Gunzburg Professor of Oncology  
McGill University  
Director, Segal Cancer Centre, Lady Davis Institute for Medical Research  
Jewish General Hospital

#### **Educational Objectives:**

1. To appreciate the successes and limitations of current cancer therapeutics approaches
2. To share perspectives on the challenges of personalized cancer care
3. To outline what role we at the JGH play in this challenge

**SEPTEMBER 26**

### **23rd ANNUAL NACHUM & BERTHA MIZNE MEMORIAL LECTURE HEPATITIS C: A TALE OF GENETICS AND DESIGNER DRUGS**

**Peter Ghali, MD**

Assistant Professor of Medicine  
Division of Gastroenterology and Hepatology  
McGill University  
Gastroenterology, Hepatology and Liver Transplantation  
MUHC, Royal Victoria Hospital

#### **Educational Objectives:**

At the end of this talk attendees should:

1. be aware of recent advances in the link between genetics and response to Hepatitis C therapy
2. be aware of new therapeutic options for hepatitis C and their limitations

**October 3**

### **DIABETES COMPLICATIONS: NEW THERAPEUTIC STRATEGIES**

**Richard E. Gilbert, MD, PhD, FRCPC**

Canada Research Chair in Diabetes Complications and Professor of Medicine, University of Toronto  
Chair of the Diabetes Section for the Canadian Hypertension Education Program (CHEP)  
Division of Endocrinology, St. Michael's Hospital  
Toronto, Ontario

#### **Educational Objectives:**

1. To examine pathogenetic mechanisms that underlie the development of diabetes complications
2. To explore new therapeutic strategies for their treatment

**October 10**

**NO ROUNDS - THANKSGIVING - Action de grâce**

**October 17**

### **CARDIOVASCULAR AND RENAL IMPLICATIONS IN HYPERTENSIVE CLINICAL TRIALS IN DIABETICS**

**Matthew R. Weir, MD**

Professor and Director, Division of Nephrology  
University of Maryland School of Medicine  
Baltimore, Maryland

#### **Educational Objectives:**

1. To understand the relationship between BP and risk for renal disease progression in diabetics
2. To appreciate the benefits of both lower BP and RAAS blockade in preventing progression of diabetic renal disease

3. To understand that the data from many clinical trials is somewhat limited due to the short duration of follow-up and decreased underlying risk for progression

**October 24**

**A PRESENTATION IN HONOUR OF JOSEPH PORTNOY, MD, FRCPC, INAUGURAL RECIPIENT OF THE AWARD FOR EXCELLENCE IN PHYSICIAN MANAGEMENT AT THE JEWISH GENERAL HOSPITAL  
THE REBUILDING OF OUR HEALTH CARE SYSTEM: OUR ROLE AS PHYSICIANS**

**Jeffrey Turnbull, MD, FRCPC**

Chief of Staff and Division of Internal Medicine  
The Ottawa Hospital and University of Ottawa

**Educational Objectives:**

1. To understand the strength and challenges of our existing health care system
2. To understand a vision for a new health care system for Canada
3. To understand physicians role in making this a reality

**October 31**

**DEMENTIA IN 2011: NEW TERMS, NEW ADVANCES, NEW COMPLEXITY**

**Howard Chertkow, MD**

Professor, Department of Neurology & Neurosurgery, McGill University  
Director, Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research  
Associate Member, Division of Geriatric Medicine, Department of Medicine, Jewish General Hospital

**Educational Objectives:**

1. To appreciate the new understanding of the time course of Alzheimer's Disease and Mild Cognitive Impairment
2. To understand the growing role of biomarkers and genetic analysis in Late Onset Alzheimer's Disease
3. To appreciate the new opportunities for prevention arising from community studies, and the current status of disease modulating therapies for Late Onset Alzheimer's Disease

**November 7**

**McGILL/JGH/MERCK CANADA LIPID LECTURESHIP 2011  
BEYOND THE GENOME: SURFING THE DATA TSUNAMI OF MODERN TECHNOLOGIES**

**Manuel Mayr, MD, PhD**

British Heart Foundation Centre of Research Excellence  
King's college, London, United Kingdom

**Educational Objectives:**

1. To appreciate the impact of proteomics on vascular disease
2. To understand the impact of lipidomics on vascular disease

Evening Research Lecture

**COMBINING LIPIDOMICS, PROTEOMICS AND PLASMA MICRORNA PROFILING TO UNRAVEL NEW CLUES FOR CARDIOVASCULAR PATHOLOGIES**

**Educational Objectives:**

1. To understand the impact of lipidomics on cardiovascular disease
2. To understand the impact of proteomics on cardiovascular disease
3. To understand the impact of microRNA on cardiovascular disease

**November 14**

**ARTERIAL AGING AS A POSSIBLE MARKER OF COGNITIVE DYSFUNCTION**

**Angelo Scuteri, MD, PhD**

Specialist in Geriatric Medicine  
UOC Geriatria -INRCA IRCCS  
Professor of Medicine -School of Medicine -University "Tor Vergata"  
Rome, Italy

**Educational Objectives:**

1. To describe the cross-talk between arterial and brain aging in order to highlight that cognitive dysfunction might be prevented and/or postponed
2. To propose some clinically relevant arterial parameters as potential markers of arterial aging and of cognitive dysfunction
3. To propose a conceptual framework from clinical and translational research in which the disability in older subjects might be prevented by targeting factors modulating the aging process (CV disease-related morbidity and arterial aging, in our case)

Contact Person: José Morais, MD, Chief, Division of Geriatric Medicine, Tel. 514-340-7501.

**November 21**

**EARLY DIAGNOSES OF MELANOMA: NEW TECHNOLOGY FROM DERMOSCOPY TO CONFOCAL MICROSCOPY TO MELAFIND, A NEW COMPUTERIZED ANALYSIS OF MOLES**

**Robin Billick, MD**

Associate Professor of Medicine

McGill University  
Chief, Division of Dermatology  
Jewish General Hospital

**Educational Objective:**

To learn new technologies and techniques for the early diagnosis of melanoma

**November 28**

**UPDATE ON THE TREATMENT OF INFLAMMATORY BOWEL DISEASE**

**Waqas Afif MD, FRCPC**

Professor of Medicine  
McGill University  
Division of Gastroenterology (Adult)  
Royal Victoria Hospital  
McGill University Health Centre  
Educational Objectives:

1. Review the management of moderate to severe IBD in the outpatient setting
2. Review the management of IBD in the hospitalized patient

**DECEMBER 5**

**CARDIOTOXICITY IN CHEMOTHERAPY-TREATED PATIENTS: THERAPEUTICS AND EARLY PREDICTORS**

**Richard Sheppard MD, FRCPC**

**& Igal A. Sebag, MD, FRCPC**

Division of Cardiology  
McGill University and Jewish General Hospital

**Educational Objectives:**

1. Discuss the epidemiology of chemotherapy-induced cardiotoxicity in the context of the various agents being used for the treatment of various malignancies
2. Discuss the current approach to treatment of established cardiomyopathy from chemotherapeutic agents in the treatment of both hematologic and solid tumors
3. Review the data supporting the use of early markers for the prediction of chemotherapy-induced cardiotoxicity in patients with breast cancer
4. Explore new avenues for integrating this information into an algorithmic approach to avoid and/or limit cardiotoxicity in these patients

**December 12**

**CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE AND ANTIBIOTICS ; GUILT BY ASSOCIATION ?**

**Sandra Dial, MD, MSc**

Critical Care Medicine  
Jewish General Hospital and Montreal Chest Institute  
Respiratory Epidemiology and Clinical Research Unit  
McGill University

**Educational Objectives:**

1. Review of the limitations in the literature regarding the association of specific antibiotics with C.difficile
2. Understand how certain hospital practices with examples from the MUHC could lead to confounded associations
3. Review the concept of confounding by indication

**January 9**

**RESIDENT RESEARCH IN HEMATOLOGY AND THE CLINICIAN INVESTIGATOR PROGRAM**

**Mark Blostein, MD, FRCPC**

Associate Professor of Medicine  
Director, Clinical Investigator Program  
McGill University  
Director, Coagulation Laboratories and Anticoagulation Clinic  
Division of Hematology, Department of Medicine  
Jewish General Hospital

**Michael Goldfarb, MD**

Resident in Internal Medicine

**& Mandana Rasti, MD**

Resident in Internal Medicine, Jewish General Hospital and McGill University

**Educational Objectives:**

1. The description of the Clinical Investigator Program at McGill University
2. Demonstration of peer review published work initiated and completed by internal medicine residents

**January 16**

**THE E.D. ASTHMA PROTOCOL OR HOW TO MANAGE ACUTE ASTHMA**

**Pierre Ernst, MD**

Professor of Medicine, McGill University

Division of Pulmonary, Jewish General Hospital

**& Denny P. Laporta, MD, FRCPC**

Assistant Professor of Medicine, McGill University

Member of Departments of Medicine (Division of Pulmonary) and Adult Critical Care, Jewish General Hospital

**Educational Objectives:**

1. To become aware of the standard algorithm for the management of acute asthma in the ED being instituted at the JGH
2. To recognize the importance of objective measures of airways obstruction in the ED
3. To be aware of the management of acute asthma across the spectrum of severity of attacks

**January 23**

**CONCERNS FOR THE FUTURE OF HIV THERAPY: CAN OUR PROGRESS BE SUSTAINED?**

**Mark Wainberg, PhD**

Professor and Director, McGill AIDS Centre, McGill University

Researcher, Lady Davis Institute for Medical Research

**Educational Objectives:**

1. The audience will gain a better appreciation of how HIV drug resistance develops
2. The audience will gain insight as to how different drug resistance mutations in tandem can influence levels of drug resistance in a clinically relevant yet non-predictable way
3. The audience will gain insight into how and why more ultrasensitive methods than those that are now commonplace should be used to screen for HIV drug resistance in previously untreated patients

**January 30**

**ZESCA (ZYBAN AS AN EFFECTIVE SMOKING CESSATION AID): TRIALS AND TRIBULATIONS**

**Mark J. Eisenberg, MD, MPH**

Professor of Medicine, Divisions of Cardiology and Clinical Epidemiology

McGill University and Jewish General Hospital

**Educational Objectives:**

1. Learn how to design and conduct a clinical trial
2. Learn about the effectiveness of bupropion for smoking cessation in hospitalized patients with acute myocardial infarction

**February 6, 2012**

**SIXTEENTH ANNUAL HUMANIZATION OF CARE AWARENESS PROGRAM**

**FOCUS ON COMMUNICATION**

**Jacki Raboy Thaw BSc.N CNCC(C)**

Nurse Coordinator - Intensive Care Unit

**Paul Warshawsky, MD**

Assistant Professor of Medicine, McGill University

Chief, Department of Adult Critical Care

Division of Pulmonary, Department of Medicine, JGH

**Denny P. Laporta MD, FRCPC**

Assistant Professor of Medicine, McGill University

Member of Departments of Medicine, Division of Pulmonary and Adult Critical Care, JGH

**Educational Objectives:**

1. To understand how effective communication results in better and safer patient care
2. To learn about the ongoing initiatives at the JGH to help improve communication

**February 13**

**INTERESTING CASES AT THE JEWISH GENERAL HOSPITAL**

**Mark Davis, MD & Ahd Al-Khunaizi, MD**

First & Third Year Internal Medicine Residents, McGill University & Jewish General Hospital

**Supervisor: Ruxandra Bunea, MD**

Assistant Professor of Medicine, McGill University & Director, Postgraduate Education, JGH

**Educational Objectives:**

1. To recognize the possibility of severe hepatotoxicity associated with Lamisil.
2. To better understand how to diagnose insulinoma.
3. To gain a better understanding of treatment options for insulinoma.

**February 20**

**CRITICAL ILLNESS ASSOCIATED BRAIN DYSFUNCTION**

**Pratik Pandharipande, MD, MSCI**

Associate Professor of Anesthesiology and Critical Care

Vanderbilt University School of Medicine

**Educational Objectives:**

1. To understand the prevalence and risk factors of critical illness associated brain dysfunction
2. To understand the outcomes associated with critical illness associated brain dysfunction
3. To identify prevention and treatment strategies for critical illness associated brain dysfunction

**February 27**

**MONITORING PATIENTS ON OPIOIDS**

**Beth-Ann Cummings, MD**

Assistant Professor of Medicine, McGill University  
Undergraduate Education Director, Department of Medicine, JGH  
Division of Internal Medicine, Opioid Monitoring Committee, JGH

**Educational Objectives:**

1. Understand the need for hospital-wide guidelines for monitoring patients receiving opioids
2. Understand the role of the MD in prescribing and monitoring opioids
3. Recognize the importance of inter-professional collaboration in this context

**March 5**

**THE HAITIAN CHOLERA EPIDEMICS**

**Amos Hercz, MD**

Assistant Professor, Montreal University  
Division of Internal Medicine, Santa Cabrini Hospital, CHUM

**Educational Objectives:**

1. To understand the origins of the 2010-2011 cholera epidemic in Haiti
2. To appreciate the challenges involved in responding to this complex humanitarian emergency

**March 12**

**Evolution of the Medical Geneticist-RaDiCAL Thoughts**

**David S. Rosenblatt, MD**

Dodd Q. Chu and Family Chair in Medical Genetics, Chairman, Department of Human Genetics  
Professor, Departments of Human Genetics, Medicine, Pediatrics, and Biology, McGill University  
Chief, Division of Genetics and Department of Medical Genetics, Jewish General Hospital

**Educational Objectives:**

1. To explain the role of the medical geneticist
2. To give a perspective on how to approach DNA based tests for "genetic" disease.
3. To give an example of the use of next generation approaches to diagnosis.

**March 19**

**ZESCA (ZYBAN AS AN EFFECTIVE SMOKING CESSATION AID): TRIALS AND TRIBULATIONS**

**Mark J. Eisenberg, MD, MPH**

Professor of Medicine, Divisions of Cardiology and Clinical Epidemiology  
McGill University and Jewish General Hospital

**Educational Objectives:**

1. Learn how to design and conduct a clinical trial
2. Learn about the effectiveness of bupropion for smoking cessation in hospitalized patients with acute myocardial infarction

**March 26**

**NEW ORAL ANTICOAGULANTS**

**Mark Blostein, MD, FRCPC**

Associate Professor of Medicine & Director, Clinical Investigator Program, McGill University  
Director, Coagulation Laboratories and Anticoagulation Clinic, Division of Hematology, Department of Medicine, Jewish General Hospital

**&**

**Susan R. Kahn MD, MSc, FRCPC**

Professor of Medicine, McGill University  
Director, Thrombosis Program & Fellowship  
Division of Internal Medicine, Department of Medicine & Center for Clinical Epidemiology and Community Studies, Jewish General Hospital

**Educational Objectives:**

1. To learn about mechanisms of action of new oral anticoagulants
2. To review clinical trial data on their effectiveness and safety
3. To discuss "real-life" use of these new drugs for atrial fibrillation and venous thrombosis

**April 2**

**COGNITION AND FALLS IN THE ELDERLY: THE COLLUSION OF TWO GIANTS**

**Manuel Montero-Odasso, MD, PhD**

Associate Professor, Department of Medicine, Epidemiology and Biostatistics,  
University of Western Ontario

**Educational Objectives:**

1. To summarize the evidences that link cognitive function to gait and fall risk in older adults.
2. To describe how and why some aspect of cognition, such as executive function, are closely related to fall risk while general measures of cognitive function, for example the MMSE, are often not closely related to falls among community-dwelling healthy seniors.

3. To review the growing body of literature that supports the concept that cognitive remediation treatments are useful for enhancing gait, improving mobility and reducing fall risk in older individuals

**April 9**

**NO ROUNDS EASTER MONDAY**

**April 16**

**EMERGING THERAPIES FOR TREATING SEVERE ASTHMA**

**Richard Leigh, MD**

Associate Professor of Medicine, Physiology and Pharmacology, University of Calgary  
GSK-CIHR Professor of Inflammatory Lung Disease, Division of Respiratory Medicine, University of Calgary

**Educational Objectives:**

1. Review need for objective assessments in managing severe asthma
2. Discuss the prevalence of non-adherence with medication in a difficult-to-treat asthma population
3. Discuss emerging therapies for treating severe asthma

**April 23**

**IMMUNOTHERAPY - UPDATE 2012 AND BEYOND**

**Peter Small, MD**

Associate Professor of Medicine, McGill University  
Chief, Division of Allergy and Immunology, Jewish General Hospital

**Educational Objectives:**

- 1: Understand the role of Immunotherapy in allergic diseases.
- 2: Become aware of the new treatment options now available.

**April 30**

**CONTROVERSIAL TOPICS IN BREAST PATHOLOGY**

**Anca Florea, MD**

Assistant Professor of Pathology, McGill University  
Staff, Department of Pathology, Jewish General Hospital

**Educational Objectives:**

1. To improve their knowledge on the papillary lesions of the breast in terms of classification, differential diagnosis and treatment
2. To improve their understanding of the "breast tumor heterogeneity" concept

**May 7**

**ENDOSCOPIC HEMOSPRAW IN MALIGNANT UPPER GASTROINTESTINAL BLEEDING**

**Yen-I Chen, MD**

Second Year Internal Medicine Resident, McGill University & Jewish General Hospital  
Supervisor: Alan Barkun, MD,CM, MSc Douglas G. Kinnear Chair in Gastroenterology, Professor of Medicine, McGill University

**Educational Objectives:**

1. Review the current management of malignant upper gastrointestinal bleeding
2. Describe the use of Hemospray, a novel endoscopic modality, in GI hemorrhage
3. Review our preliminary experience of its use in tumor bleeding (first cases worldwide)

**&**

**Silencing Expertise in the Development Of International Clinical Practice Guidelines: Conflicts of Interest Ethics**

**Yidan Lu, MD** Second Year Internal Medicine Resident, McGill University and Jewish General Hospital

**Supervisor: Alan Barkun, MD,CM, MSc** Douglas G. Kinnear Chair in Gastroenterology, Professor of Medicine, McGill University

Chief Quality Officer, Division of Gastroenterology, McGill University and MUHC

**Educational Objectives:**

1. Review the current conflicts of interest management strategies in clinical practice guideline development
2. Understand the rationale for an ethics framework in the development of an international guideline where experts with conflicts of interest vote, but do not participate in discussion
3. Describe the voting outcomes when including and excluding experts with conflicts of interest

**May 14**

**RESEARCH ETHICS ROUNDS**

**SECURITY OF RESEARCH DATA: WHAT YOU SHOULD KNOW**

**Martin Fiset**

President Cryptofiz  
Information Security Consultant in mandate as a Senior Security Analyst  
Security Governance at MUHC

**Educational Objectives:**

1. To identify what is important to ensure a secured database.

2. To differentiate between two cloud services, which one offers the best protection to their health research data.
3. To better estimate the effort needed to comply with the security triade of CIA (confidentiality, integrity & availability)

**May 21**

**No Rounds - Victoria Day Holiday**

**May 28**

**THE SIMON DWORKIN LECTURE IN RHEUMATOLOGY**

**IgG4-RELATED DISEASE**

**John H. Stone, MD, MPH**

Director, Clinical Rheumatology, Massachusetts General Hospital  
Associate Professor of Medicine, Harvard Medical School

**Educational Objectives:**

1. To understand the clinical breadth of the emerging clinical condition known as IgG4-related disease
2. To become familiar with the preferred nomenclature for individual organ system manifestations of this disorder
3. To identify the cardinal pathological features of IgG4-related disease, both histopathology and immunostaining
4. To recognize lessons derived from targeted biologic therapy in this disease, and understand the implications for pathogenesis and immune system function

**June 4**

**MY NEW PATIENT IS A RECENT ARRIVAL FROM CAMEROUN - WHAT DO I NEED TO WATCH OUT FOR?**

**Christina Greenaway, MD**

Associate Professor of Medicine, McGill University  
Staff Physician, Division of Infectious Diseases, Jewish General Hospital

**Educational Objectives:**

1. To understand the recent and changing epidemiology of health problems in refugees and immigrants in Canada
2. To become familiar with the opportunities to positively affect the health of Canadian refugees and immigrants
3. To become familiar with the new guidelines for the screening and treatment of medical problems in Canadian refugees and immigrants

**June 11**

**JGH AT THE CUTTING-EDGE OF RESEARCH IN MALIGNANT HEMATOLOGY**

**Sarit Assouline, MD**

Assistant Professor of Medicine  
McGill University  
Division of Hematology  
Jewish General Hospital

**Educational Objectives:**

1. Understanding the developments in the treatment of CML (Chronic Myelogenous Leukemia) including the outcomes with imatinib, new drug development, and a possibility of cure for some patients
2. Introduction to GA101, a new monoclonal antibody for the treatment of B cell lymphomas on the not so distant horizon
3. Understanding new research methodology in order to better target therapies in malignant hematology, what we are doing at the JGH
4. AML (Acute Myelogenous Leukemia) landscape: have we made progress in the treatment of relapsed disease?

**June 18**

**CARDIAC SURGERY OUTCOMES 2011 AND VISION**

**Yves Langlois, MD**

Associate Professor of Surgery, McGill University; Staff, Cardiac Surgery, Jewish General Hospital

**Felix Ma, MD**

Assistant Professor of Surgery, McGill University; Staff, Cardiac Surgery, Jewish General Hospital

**& Jean-Francois Morin, MD**

Associate Professor of Surgery, McGill University; Interim Chief, Cardiac Surgery, Jewish General Hospital

**Educational Objectives:**

1. To learn about the outcomes of your patients who undergo cardiac surgery
2. To witness the evolution and vision of cardiac surgery division at the JGH